Czech law does not currently permit the mail-order dispensing of prescription-only medicines. The Ministry of Health is preparing draft legislation that could create a controlled route for Rx medicines under defined conditions. The central issue is not merely whether the market opens, but whether pharmaceutical assessment, counselling, identity checks, transport and handover form one safe dispensing process.
What applies on 5 October 2026
Section 85(1) of Czech Act No. 378/2007 on Pharmaceuticals limits mail-order dispensing to registered medicines whose supply is neither restricted nor subject to medical prescription. There is therefore still no regular Czech mail-order route for prescription-only medicines.
The current SÚKL guideline LEK-16 version 7 has applied since 2 January 2026. It sets out the authority's principles for the existing pharmacy mail-order model, is recommendatory, and does not override the statutory exclusion of prescription-only medicines.
A policy proposal is not yet enacted law
The Ministry of Health has announced that a draft will enter its internal consultation process in October 2026. A dedicated working group on mail-order dispensing has existed within the Ministry's Medicines Policy Advisory Board since January 2026. The final product scope, operating rules, commencement date and transitional arrangements have not been settled. Implementation will depend on the full legislative process.
January 2028 should therefore not be presented as an enacted commencement date. At most, it is a political planning target that may change.
Where controlled Rx delivery may improve access
A regulated service could help people for whom reaching a pharmacy is a genuine barrier: patients with reduced mobility, stable long-term therapy, post-operative restrictions, carers and residents of communities with few pharmacies or poor transport. It should complement local pharmacy care rather than replace accessible pharmaceutical support.
Pharmaceutical assessment must precede dispatch release
An electronic order must not automatically release a medicine for shipping. Each dispensing needs an accountable pharmaceutical checkpoint. Depending on the case, this includes prescription validity and assignment, patient and recipient identity, dose, duplicate therapy, interactions, contraindications, visible adherence concerns and the medicine's suitability for the chosen transport and handover model.
Future rules should clearly define excluded medicines and situations requiring enhanced approval. Product risk, misuse potential, special monitoring, temperature sensitivity and urgent treatment cannot be absorbed into one generic workflow.
Counselling is part of dispensing
Public descriptions of the proposal retain the pharmacist's professional role. Some cases would require direct contact by telephone or video; in others, the pharmacist would decide whether consultation is necessary. Patients should always be entitled to request counselling.
A safe system needs documented triggers: a new therapy, dose change, complex administration, possible interaction, unclear prescription, recognised use problem or doubt about safe delivery. Standard electronic information does not replace a personal consultation in those situations.
Transport and handover must protect the medicine
The pharmacy's responsibility cannot end when a parcel is passed to a carrier or placed in a locker. Packaging, transit time, temperature, intermediate storage, tamper protection, failed delivery and returns must be controlled for the medicine and lane. Temperature-sensitive medicines need qualified packaging, defined maximum times and usable temperature evidence.
Parcel lockers can only be considered for suitable medicines and validated processes. Secure recipient verification, limited holding time, protection from heat and freezing, and controlled handling of uncollected or deviating shipments are essential. A returned medicine must not automatically re-enter dispensable stock without a documented quality decision.
Quality architecture required before launch
- clear pharmaceutical accountability and documented release for each shipment,
- reliable verification of the patient and authorised recipient,
- rules for prescription, medication and counselling review,
- product-specific eligibility and exclusion criteria,
- risk-based packaging, temperature and maximum-transit concepts,
- qualified carriers with data, information and audit rights,
- controlled deviations, complaints, returns, recalls and CAPA,
- measurable quality indicators and effective regulatory oversight,
- accessible counselling for patients without digital confidence.
Market opening requires demonstrable quality of care
Potential Czech Rx mail order is not simply an e-commerce project or a logistics question. It changes one part of medicine dispensing. Patient safety, pharmaceutical judgement and continuity of therapy must therefore come before speed and reach.
Pharmacies, logistics providers and technology companies can prepare process variants, medicine classes, counselling routes, interfaces, temperature concepts and QMS evidence now. Operational Rx mail order must nevertheless wait for the final Czech legal framework and the requirements subsequently published by the competent authorities.
Sources and information status
- SÚKL: LEK-16 version 7 – principles of pharmacy mail-order dispensing
- Czech Ministry of Health: Medicines Policy Advisory Board and working group on mail-order dispensing
- ČTK/Novinky, 29 September 2026: announced draft and current planning status
Professional analysis as at 5 October 2026. The enacted legislation and subsequent requirements published by the competent Czech authorities will be decisive.